Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Dumaz

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Clinical and Translational Medicine|October 25, 2023
Unmasking the tumourigenic role of SIN1/MAPKAP1 in the mTOR complex 2Emilien Ezine, Céleste Lebbe, Nicolas Dumaz
Biomedicines|October 23, 2021
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted TherapyAhlem Jebali, Maxime Battistella, Céleste Lebbé, et al.
Archivum Immunologiae Et Therapiae Experimentalis|December 7, 2007
Recent discoveries in the genetics of melanoma and their therapeutic implicationsAmélie Marquette, Martine Bagot, Armand Bensussan, et al.
Nature Structural & Molecular Biology|April 12, 2011
ERK and PDE4 cooperate to induce RAF isoform switching in melanomaAmélie Marquette, Jocelyne André, Martine Bagot, et al.
Molecular and Cellular Endocrinology|December 3, 2016
Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistanceEmmanuelle Motte, Catherine Le Stunff, Claire Briet, et al.
Cancers|August 11, 2019
Atypical <i>BRAF</i> and <i>NRAS</i> Mutations in Mucosal MelanomaNicolas Dumaz, Fanélie Jouenne, Julie Delyon, et al.
Melanoma Research|October 12, 2014
Driver KIT mutations in melanoma cluster in four hotspotsNicolas Dumaz, Jocelyne André, Aurélie Sadoux, et al.
Human Pathology|May 14, 2013
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutationsMeriem Chraybi, Issam Abd Alsamad, Christiane Copie-Bergman, et al.
Oncotarget|September 11, 2015
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanomaFlorence Laugier, Adeline Finet-Benyair, Jocelyne André, et al.
Current Opinion in Oncology|December 14, 2020
Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical dataPauline Tétu, Laetitia Vercellino, Coralie Reger de Moura, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Clinical and Translational Medicine|October 25, 2023
Unmasking the tumourigenic role of SIN1/MAPKAP1 in the mTOR complex 2Emilien Ezine, Céleste Lebbe, Nicolas Dumaz
Biomedicines|October 23, 2021
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted TherapyAhlem Jebali, Maxime Battistella, Céleste Lebbé, et al.
Archivum Immunologiae Et Therapiae Experimentalis|December 7, 2007
Recent discoveries in the genetics of melanoma and their therapeutic implicationsAmélie Marquette, Martine Bagot, Armand Bensussan, et al.
Nature Structural & Molecular Biology|April 12, 2011
ERK and PDE4 cooperate to induce RAF isoform switching in melanomaAmélie Marquette, Jocelyne André, Martine Bagot, et al.
Molecular and Cellular Endocrinology|December 3, 2016
Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistanceEmmanuelle Motte, Catherine Le Stunff, Claire Briet, et al.
Cancers|August 11, 2019
Atypical <i>BRAF</i> and <i>NRAS</i> Mutations in Mucosal MelanomaNicolas Dumaz, Fanélie Jouenne, Julie Delyon, et al.
Melanoma Research|October 12, 2014
Driver KIT mutations in melanoma cluster in four hotspotsNicolas Dumaz, Jocelyne André, Aurélie Sadoux, et al.
Human Pathology|May 14, 2013
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutationsMeriem Chraybi, Issam Abd Alsamad, Christiane Copie-Bergman, et al.
Oncotarget|September 11, 2015
RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanomaFlorence Laugier, Adeline Finet-Benyair, Jocelyne André, et al.
Current Opinion in Oncology|December 14, 2020
Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical dataPauline Tétu, Laetitia Vercellino, Coralie Reger de Moura, et al.
Pageof 5